CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-09. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
FDA pediatric label approval for Casgevy down to age 2 broadens the eligible addressable patient population following 78% quarter-over-quarter sales expansion to $76 million for CRISPR Therapeutics.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factCRISPR Therapeutics recorded $76 million in Q2 sales for gene-editing therapy Casgevy, representing 78% quarter-over-quarter growth. |
| What else was confirmed? | Reported factThe U.S. FDA granted label expansion approval for Casgevy in pediatric patients aged 2 years and older. |
| Does the valuation support acting? | UnknownNo stored valuation assumptions for CRSP yet — this is the next research task. |
| What would change the assessment? | UnknownCasgevy commercial infusion volumes — Updates on active qualified treatment centers and pediatric patient intake. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · CRISPR Therapeutics recorded $76 million in Q2 sales for gene-editing therapy Casgevy, representing 78% quarter-over-quarter growth.
- · The U.S. FDA granted label expansion approval for Casgevy in pediatric patients aged 2 years and older.
- · CRISPR Therapeutics shares rallied nearly 19% across the month of August following commercial and regulatory progress.
Public research record
Research framework · page evidenceCompleted event assessment
commercial product revenue growth and expanded FDA label indication
| Type | Claim | Scope |
|---|---|---|
| Assumption | CRISPR Therapeutics recorded $76 million in Q2 sales for gene-editing therapy Casgevy, representing 78% quarter-over-quarter growth. | 2026-09-09 |
| Interpretation | commercial product revenue growth and expanded FDA label indication | CRSP |
Countercase, invalidators, and sources
Pediatric center activations accelerate patient onboarding, sustaining sequential sales growth above 50%.
- · Casgevy commercial infusion volumes — Updates on active qualified treatment centers and pediatric patient intake.
- Why CRISPR Therapeutics Stock Rocked the Market Last Month · 2026-09-08
What remains unresolved
- Base path
- Casgevy clinical adoption steadily scales across qualified treatment centers under the expanded label.
- Adverse path
- Reimbursement negotiations or hospital administration bottlenecks slow patient therapy throughput.
- Supportive path
- Pediatric center activations accelerate patient onboarding, sustaining sequential sales growth above 50%.
- · Casgevy commercial infusion volumes — Updates on active qualified treatment centers and pediatric patient intake.this week
Evidence
- Why CRISPR Therapeutics Stock Rocked the Market Last Month2026-09-08
“CRISPR Therapeutics stock surged nearly 19% in August following strong Q2 earnings. The company's approved blood disorder treatment Casgevy saw 78% quarter-over-quarter sales growth to $76 million, and the FDA approved its label expansion for pediatric patients aged 2 and older.”
Supports: Casgevy saw 78% QoQ sales growth to $76M and FDA approved label expansion for pediatric patients aged 2 and older.